BSE SENSEX
37,388.66+835.06(+2.28%)Nifty 50
11,050.25+244.70(+2.26%)USD/INR
73.7070-0.1900(-0.26%)
Vertex Pharmaceuticals Incorporated (VRTX)
267.00 -1.18 (-0.44%)
After hours: 6:29PM EDT
| Previous close | 263.13 |
| Open | 264.10 |
| Bid | 263.00 x 900 |
| Ask | 268.00 x 800 |
| Day's range | 260.52 - 268.91 |
| 52-week range | 165.23 - 306.08 |
| Volume | 1,258,324 |
| Avg. volume | 1,318,617 |
| Market cap | 69.852B |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | 33.85 |
| EPS (TTM) | 7.92 |
| Earnings date | 28-Oct-2020 - 02-Nov-2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 306.43 |
- Business Wire
FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO® (ivacaftor) for use in children with cystic fibrosis (CF) ages four months to less than six months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to KALYDECO based on clinical and/or in vitro assay data. KALYDECO is already approved in the U.S. and EU for the treatment of CF in patients ages six months and older.
- Business Wire
Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA open-label extension study, which showed safety and efficacy consistent with the results of the Phase 3 pivotal studies in patients with CF ages 12 and older with F508del/Minimal Function (F/MF) or F508del/F508del (F/F) genotypes. Four additional scientific abstracts for ORKAMBI® and TRIKAFTA® were published in the Journal of Cystic Fibrosis as part of the ECFS conference. In addition, six scientific presentations will occur at NACFC regarding KALYDECO,® ORKAMBI and TRIKAFTA, including new data from KALYDECO in infants ages 4 to less than 6 months old.
- Zacks
CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.
